$MRK News Article - LYNPARZA (olaparib) More Than Doubled Median Radiographic Progression-Free Survival (rPFS) in BRCA1/2 or ATM Metastatic Castration-Resistant Prostate Cancer vs. Standard of Care (7.4 vs. 3.6 months)
https://marketwirenews.com/news-releases/lynp...35142.html